Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 2
1998 1
1999 1
2000 2
2001 1
2002 4
2003 3
2004 2
2007 2
2008 14
2009 7
2010 3
2011 5
2012 13
2013 7
2014 4
2015 4
2016 1
2017 2
2018 2
2019 5
2020 8
2021 1
2022 6
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM. Galluzzi L, et al. Among authors: melcher aa. J Immunother Cancer. 2020 Mar;8(1):e000337. doi: 10.1136/jitc-2019-000337. J Immunother Cancer. 2020. PMID: 32209603 Free PMC article. Review.
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
Patin EC, Dillon MT, Nenclares P, Grove L, Soliman H, Leslie I, Northcote D, Bozhanova G, Crespo-Rodriguez E, Baldock H, Whittock H, Baker G, Kyula J, Guevara J, Melcher AA, Harper J, Ghadially H, Smith S, Pedersen M, McLaughlin M, Harrington KJ. Patin EC, et al. Among authors: melcher aa. J Immunother Cancer. 2022 Mar;10(3):e004306. doi: 10.1136/jitc-2021-004306. J Immunother Cancer. 2022. PMID: 35314434 Free PMC article.
Recent clinical experience with oncolytic viruses.
Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R, Melcher AA. Donnelly OG, et al. Among authors: melcher aa. Curr Pharm Biotechnol. 2012 Jul;13(9):1834-41. doi: 10.2174/138920112800958904. Curr Pharm Biotechnol. 2012. PMID: 21740364 Review.
Oncolytic viruses: a novel form of immunotherapy.
Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Prestwich RJ, et al. Among authors: melcher aa. Expert Rev Anticancer Ther. 2008 Oct;8(10):1581-8. doi: 10.1586/14737140.8.10.1581. Expert Rev Anticancer Ther. 2008. PMID: 18925850 Free PMC article. Review.
89 results